Alida Dominietto
Overview
Explore the profile of Alida Dominietto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
La Rocca U, Ricci R, Piciocchi A, Barberi W, Oldani E, Dominietto A, et al.
Blood Transfus
. 2025 Feb;
PMID: 39949023
Background: Antibodies directed against donor-specific HLA allele(s)/antigen(s) (DSAs) represent a known risk factor for hematopoietic stem cell transplantation (HSCT) engraftment. Still, the overall management needs to be standardized. Material And...
2.
Di Francesco A, Raiola A, Dominietto A, di Grazia C, Gualandi F, Van Lint M, et al.
Front Med (Lausanne)
. 2024 Feb;
10:1320692.
PMID: 38327272
We studied the incidence of acute graft versus host disease (GvHD) and its outcome in three consecutive time frames (year <2000; 2000-2010; >2010), in 3,120 patients allografted in two transplant...
3.
Raiola A, di Grazia C, Dominietto A, Bregante S, Giammarco S, Varaldo R, et al.
Blood Adv
. 2024 Feb;
8(8):1964-1967.
PMID: 38324723
No abstract available.
4.
Balletto E, Ponzano M, Raiola A, Gambella M, di Grazia C, Dominietto A, et al.
Transpl Infect Dis
. 2024 Jan;
26(2):e14215.
PMID: 38192010
Background: Adenovirus infection (ADVi) is an emergent complication in adult patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is associated with poor outcome. Available data on risk factors and...
5.
Montoro J, Boumendil A, Finel H, Bramanti S, Castagna L, Blaise D, et al.
Transplant Cell Ther
. 2023 Dec;
30(2):210.e1-210.e14.
PMID: 38043802
Post-transplantation cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the...
6.
Dominietto A, Vagge S, di Grazia C, Bregante S, Raiola A, Varaldo R, et al.
Transplant Cell Ther
. 2023 Apr;
29(8):506.e1-506.e6.
PMID: 37094701
Second allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option for patients with acute leukemia who relapse after a first HSCT. Although myeloablative conditioning (MAC) regimens before the first...
7.
Mussetti A, Kanate A, Wang T, He M, Hamadani M, Finel Sr H, et al.
Transplant Cell Ther
. 2022 Dec;
29(3):184.e1-184.e9.
PMID: 36577482
When using post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis for lymphoma patients, it is currently unknown whether a matched unrelated donor (MUD) or a haploidentical related donor is preferable if...
8.
Tagliafico A, Valle C, Bonaffini P, Attieh A, Bauckneht M, Belgioia L, et al.
Diagnostics (Basel)
. 2022 Aug;
12(8).
PMID: 36010244
To assess the reliability of the myeloma spine and bone damage score (MSBDS) across multiple readers with different levels of expertise and from different institutions. A reliability exercise, including 104...
9.
Metafuni E, Cavattoni I, Lamparelli T, Raiola A, Ghiso A, Galaverna F, et al.
Blood Adv
. 2021 Dec;
6(7):2309-2318.
PMID: 34920451
The aim of this study was to develop a predictive score for moderate-severe chronic graft-versus-host disease (cGVHD) on day +100 after allogeneic stem cell transplantation (HSCT). We studied 1292 patients...
10.
Guolo F, Minetto P, Pesce S, Ballerini F, Clavio M, Cea M, et al.
Front Immunol
. 2021 Nov;
12:753890.
PMID: 34804039
Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The...